When technological discontinuities and disruptive business models challenge dominant industry logics: insights from the drugs industry
暂无分享,去创建一个
Vincent Mangematin | Valérie Sabatier | Adrienne Kennard | V. Mangematin | V. Sabatier | Adrienne Kennard | Valérie Sabatier
[1] George Wright,et al. Confronting Strategic Inertia in a Top Management Team: Learning from Failure , 2002 .
[2] W. Powell,et al. Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. , 1996 .
[3] Constance E. Helfat,et al. Organizational Linkages for Surviving Technological Change: Complementary Assets, Middle Management, and Ambidexterity , 2008, Organ. Sci..
[4] M. Tushman,et al. On the Organizational Determinants of Technological Change: Towards a Sociology of Technological Evolution , 1992 .
[5] Robert Phaal,et al. A framework for mapping industrial emergence , 2011 .
[6] C. Prahalad,et al. The dominant logic: A new linkage between diversity and performance , 1986 .
[7] James M. Utterback,et al. Responding to Structural Industry Changes: A Technological Evolution Perspective , 1997 .
[8] D. Light,et al. Demythologizing the high costs of pharmaceutical research , 2011 .
[9] C. Prahalad. The Blinders of Dominant Logic , 2004 .
[10] G. Krogh,et al. Exploring the Link between Dominant Logic and Company Performance , 2000 .
[11] D. Teece. Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .
[12] M. Storper. The Regional World: Territorial Development in a Global Economy , 1997 .
[13] M. Tushman,et al. Technological Discontinuities and Dominant Designs: A Cyclical Model of Technological Change , 1990 .
[14] Yu-Shan Su,et al. Spontaneous vs. policy-driven: The origin and evolution of the biotechnology cluster , 2009 .
[15] Ict Access,et al. Working Party on the Information Economy , 2007 .
[16] K. Marino,et al. Developing consensus on firm competencies and capabilities , 1996 .
[17] J. Leker,et al. Anticipating converging industries using publicly available data , 2010 .
[18] R. George. Intellectual property and pharmaceutical drugs: an ethical analysis. , 2005 .
[19] Mary J. Benner. Securities Analysts and Incumbent Response to Radical Technological Change: Evidence from Digital Photography and Internet Telephony , 2010, Organ. Sci..
[20] Kjell Grønhaug,et al. Structure and Strategy in Grocery Retailing: A Sociometric Approach , 1985 .
[21] Sidney G. Winter,et al. Schumpeterian Competition in Alternative Technological Regimes , 1983 .
[22] Andrew Lilico. Six Issues in Pharmaceuticals , 2006 .
[23] K. Pavitt. Sectoral Patterns of Technical Change : Towards a Taxonomy and a Theory : Research Policy , 1984 .
[24] K. Eisenhardt,et al. Constructing Markets and Shaping Boundaries: Entrepreneurial Power in Nascent Fields , 2009 .
[25] Mary J. Benner,et al. Process Management and Technological Innovation: A Longitudinal Study of the Photography and Paint Industries , 2002 .
[26] S. Klepper. Industry Life Cycles , 1997 .
[27] J. Reiss,et al. The global health complex , 2011 .
[28] J. Fisken,et al. Business models and investment trends in the biotechnology industry in Europe , 2002 .
[29] Gaurav Laroia,et al. Managing Drug Discovery Alliances For Success , 2005 .
[30] Robert K. Yin,et al. Applications of case study research , 1993 .
[31] V. Chiesa,et al. Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis , 2011 .
[32] Y. Doz,et al. Embedding Strategic Agility A Leadership Agenda for Accelerating Business Model Renewal , 2010 .
[33] Nikolaus Thumm,et al. Strategic Patenting in Biotechnology , 2004, Technol. Anal. Strateg. Manag..
[34] D. Bosse,et al. Bargaining power in alliance governance negotiations: evidence from the biotechnology industry , 2010 .
[35] J. Streim,et al. America's other drug problem. , 1994, Provider.
[36] G. Ginsburg,et al. Personalized medicine: revolutionizing drug discovery and patient care. , 2001, Trends in biotechnology.
[37] A. Arora,et al. The changing technology of technological change: general and abstract knowledge and the division of , 1994 .
[38] Vincent Mangematin,et al. The future of drug discovery and development: Shifting emphasis towards personalized medicine , 2010 .
[39] Christel Lane,et al. The External Sourcing of Technological Knowledge by US Pharmaceutical Companies: Strategic Goals and Inter‐organizational Relationships , 2007 .
[40] Michael H. Morris,et al. The entrepreneur's business model: toward a unified perspective , 2005 .
[41] Steven T. Walsh,et al. Integrating Innovation and Learning Curve Theory: An Enabler for Moving Nanotechnologies and Other Emerging Process Technologies into Production , 2004 .
[42] Friedrich Grosse-Dunker,et al. Sustainability Innovation Cube - A Framework to Evaluate Sustainability-Oriented Innovations , 2009 .
[43] Ursula Weisenfeld,et al. Technology management and collaboration profile: virtual companies and industrial platforms in the high‐tech biotechnology industries , 2001 .
[44] Barry L. Bayus,et al. The Market Evolution and Sales Takeoff of Product Innovations , 2002, Manag. Sci..
[45] Carine Staropoli. Cooperation in R&D in the pharmaceutical industry — The network as an organizational innovation governing technological innovation , 1998 .
[46] Xavier Lecocq,et al. Business Model Evolution: In Search of Dynamic Consistency , 2010 .
[47] M. Feldman. Organizational Routines as a Source of Continuous Change , 2000 .
[48] Charles W. L. Hill,et al. Technological Discontinuities and Complementary Assets: A Longitudinal Study of Industry and Firm Performance , 2005, Organ. Sci..
[49] Sabine Glesner,et al. Editorial , 1864, Informatik - Forschung und Entwicklung.
[50] James Mittra,et al. Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms , 2007, Technol. Anal. Strateg. Manag..
[51] C. K. Prahalad,et al. THE DOMINANT LOGIC: RETROSPECTIVE AND EXTENSION , 1995 .
[52] Harry Rothman,et al. Downstream and into deep biology: Evolving business models in ‘top tier’ genomics companies , 2006 .
[53] M. Sosna,et al. Business Model Innovation through Trial-and-Error Learning , 2010 .
[54] Vincent Mangematin,et al. From Business model to Business model portfolio in the european biopharmaceutical industry , 2010 .
[55] Oliver Gassmann,et al. Organizing Pharmaceutical Innovation: From Science‐based Knowledge Creators to Drug‐oriented Knowledge Brokers , 2005 .
[56] Ramon Casadesus-Masanell,et al. From Strategy to Business Models and onto Tactics , 2010 .
[57] Mary Tripsas,et al. 1 Technology and Industry Evolution , 2008 .
[58] C. Hill,et al. The Performance of Incumbent firms in the Face of Radical Technological Innovation , 2003 .
[59] Vincent Mangematin,et al. Do Science and Money Go Together? The Case of the French Biotech Industry , 2008 .
[60] A. Strauss,et al. The discovery of grounded theory: strategies for qualitative research aldine de gruyter , 1968 .
[61] G. Hodgkinson,et al. Cognitive Inertia in a Turbulent Market: The Case of UK Residential Estate Agents , 1997 .
[62] Kathleen M. Eisenhardt,et al. Theory Building From Cases: Opportunities And Challenges , 2007 .
[63] Louis Galambos,et al. Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation , 1998, Business History Review.
[64] James M. Utterback,et al. A dynamic model of process and product innovation , 1975 .
[65] Jaideep Anand,et al. Alliance Activity as a Dynamic Capability in the Face of a Discontinuous Technological Change , 2010, Organ. Sci..
[66] S. Hill,et al. Emerging Challenges and Opportunities in Drug Registration and Regulation in Developing Countries , 2004 .
[67] F. Rothaermel. Complementary Assets, Strategic Alliances, and the Incumbent's Advantage: An Empirical Study of Industry and Firm Effects in the Biopharmaceutical Industry , 2001 .
[68] D. Teece. Business Models, Business Strategy and Innovation , 2010 .
[69] Paul Nightingale,et al. The myth of the biotech revolution: An assessment of technological, clinical and organisational change , 2007 .
[70] T. Kuhn,et al. The Structure of Scientific Revolutions. , 1964 .
[71] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[72] M. V. Geenhuizen,et al. Does a clustered location matter for high-technology companies' performance? The case of biotechnology in the Netherlands , 2007 .
[73] R. D. De George. Intellectual property and pharmaceutical drugs: an ethical analysis. , 2005, Business ethics quarterly : the journal of the Society for Business Ethics.
[74] Walter W. Powell,et al. Biotechnology: Its origins, organization, and outputs , 2007 .
[75] Harold A. Linstone,et al. Three eras of technology foresight , 2011 .
[76] C. Gilbert. Unbundling the Structure of Inertia: Resource Versus Routine Rigidity , 2005 .
[77] Transforming the critique of Big Pharma , 2011 .
[78] Anna Nosella,et al. Characteristics of the Italian biotechnology industry and new business models: the initial results of an empirical study , 2005 .
[79] V. Mangematin,et al. Orchestrating networks in the biopharmaceutical industry: small hub firms can do it , 2010 .
[80] K. Eisenhardt. Building theories from case study research , 1989, STUDI ORGANIZZATIVI.
[81] A. Pettigrew. Longitudinal Field Research on Change: Theory and Practice , 1990 .
[82] J. DiMasi,et al. The cost of biopharmaceutical R&D: is biotech different? , 2007 .
[83] S. Walsh,et al. Managing knowledge assets under conditions of radical change: The case of the pharmaceutical industry , 2011 .
[84] Ron Bradfield,et al. Four scenarios for the future of the pharmaceutical industry , 2009, Technol. Anal. Strateg. Manag..
[85] Matthew B. Miles,et al. Qualitative Data Analysis: An Expanded Sourcebook , 1994 .
[86] Frank T. Rothaermel,et al. Technological discontinuities and interfirm cooperation: what determines a startup's attractiveness as alliance partner? , 2002, IEEE Trans. Engineering Management.
[87] N. Phillips,et al. The Birth of the 'Kodak Moment': Institutional Entrepreneurship and the Adoption of New Technologies , 2005 .
[88] A. McGahan,et al. Business-Model Innovation: General Purpose Technologies and their Implications for Industry Structure , 2010 .
[89] F. Rothaermel. Technological Discontinuities and the Nature of Competition , 2000 .
[90] F. Rothaermel. Strategic Management Journal Research Note Incumbent's Advantage through Exploiting Complementary Assets via Interfirm Cooperation , 2022 .
[91] B. S. Piachaud,et al. Outsourcing in the pharmaceutical manufacturing process: an examination of the CRO experience , 2002 .
[92] Anil K. Gupta,et al. Strategic innovation: a conceptual road map , 2001 .
[93] Arvind Parkhe,et al. Orchestrating Innovation Networks , 2006 .
[94] G. Pisano. Can science be a business? Lessons from biotech. , 2006, Harvard business review.
[95] S. Walsh,et al. IAMOT and Education: Defining a Technology and Innovation Management (TIM) Body-of-Knowledge (BoK) for graduate education (TIM BoK) , 2010 .
[96] D. Teece. Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .
[97] Friedrich Grosse-Dunker,et al. Sustainbility Innovation Cube , 2009 .